drugset / Trial / NCT03127020
Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients
Phase 2
Completed
9 enrolled
PIQUR Therapeutics AG
Charite University, Berlin, Germany · collabUniversity Hospital Freiburg · collabUniversity Hospital Munich · collabUniversity Hospital, Basel, Switzerland · collabUniversity of Stuttgart · collab
NaSingle-groupOpen-labelTreatment
Summary
The main goal of this study is to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D) as well as preliminary antitumor activity of PQR309 administered orally, as once daily capsules continuously and on intermittent schedule, in patients with relapsed or refractory lymphomas.
Timeline
- Start
- 2016-06
- Primary completion
- 2019-03-21
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bimiralisib | Small molecule | 60 mg | Oral |
| Subject | Bimiralisib | Small molecule | 80 mg | Oral |
| Subject | Bimiralisib | Small molecule | 120 mg | Oral |
| Subject | Bimiralisib | Small molecule | 140 mg | Oral |
| Subject | Bimiralisib | Small molecule | 160 mg | Oral |